Drug Database
UR

urokinase

✓ Approved

Bharat Serums and Vaccines Limited · FSHR · 小分子

什么是 urokinase?

urokinase 是一种小分子,由Bharat Serums and Vaccines Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

公司Bharat Serums and Vaccines Limited
药物类别小分子, 多克隆抗体, 重组蛋白, 多肽类, 抗体
分子靶点FSHR, LHCGR, PLAU, PLG
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

urokinase 作用于 4 个分子靶点:

FSHRfollicle stimulating hormone receptor (FSHRO, ODG1)
LHCGRluteinizing hormone/choriogonadotropin receptor (ULG5, LH/CGR)
PLAUplasminogen activator, urokinase (URK, UPA)
PLGplasminogen (HAE4)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

urokinase 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersThrombosis✓ Approved

相关研究文献

PubMedCerebrovascular diseases (Basel, Switzerland)2026-11-15

The minimally invasive soft channel brain hemorrhage evacuation for acute basal ganglia hemorrhage - small hemorrhage evacuation (MIRACLE-S) trial: rationale, design and progress.

Wang Xia X, Zeng Jun-Fa JF, Luo Lei L, Bian Hetao H et al.

Acute spontaneous intracerebral hemorrhage (ICH) is a devastating type of stroke, where patients with small and large hematomas usually make excellent and poor outcomes, respectively, regardless of treatment. However, for patients with a moderate hematoma volume (20-30 mL) in a deep hemispheric location, there is clinical equipoise as to the benefit of any surgical intervention, as the randomized evidence is limited. The minimally invasive soft-channel brain hemorrhage evacuation for acute basal ganglia hemorrhage - small hemorrhage evacuation (MIRACLE-S) trial is a multicenter, prospective, randomized, open-label, blinded-endpoint assessed trial conducted in China. Eligibility criteria are adult patients aged 18 to 80 years with spontaneous basal ganglionic ICH with a hematoma volume of 20 to 30 mL, Glasgow coma scale score 9 to 14, premorbid modified Rankin scale score 0 to 1, and systolic blood pressure <140 mmHg enrolled within 48 hours of symptom onset. Patients are randomized (1:1) to soft-channel minimally invasive surgery (scMIS; stereotactic aspiration with catheter-based urokinase thrombolysis) or guideline-based conservative medical management. The primary efficacy outcome is a hierarchical composite endpoint of death, disability (mRS scores 3 to 5), rehospitalization, and poor health-related quality of life assessed at 180 days and analyzed using a win-ratio approach. Safety outcomes include mortality, rebleeding (including puncture-tract hemorrhage), and infection within 30 days. Recruitment started January 1, 2025. As of January 10, 2026, 148 patients have been randomized at 34 active sites. The required sample size of 420 to detect a win-ratio effect size of 1.62 (P_tie=0.05) should be achieved in 2028. MIRACLE-S will clarify whether aspiration-based scMIS improves recovery as compared with best medical management in patients moderate-volume basal ganglionic ICH, which is a common clinical burden in China and other regions with high rates of ICH. ClinicalTrials.gov Identifier: NCT06688162.

PMID 43033154
阅读全文 →
PubMedJournal of clinical medicine2026-11-14

Pediatric Pleural Empyema: Disease Complexity, Contemporary Management, and Future Research Priorities.

Tarditi Gabriele G, Pisa Camilla Maria CM, Ricci Ilaria I, Civino Raffaella R et al.

Background: Pediatric pleural empyema remains a major complication of community-acquired pneumonia despite vaccination and advances in minimally invasive treatment. This narrative review summarizes current evidence on etiology and microbiology, diagnosis and imaging, antimicrobial therapy, supportive care, pleural drainage, fibrinolysis, surgery, complications, and short- and long-term outcomes. Methods: This structured narrative review searched PubMed from inception through 30 July 2026. No formal risk-of-bias assessment was performed. Of 42 publications assessed in full, 38 were included in the narrative synthesis. Results: Streptococcus pneumoniae, particularly serotype 3, Staphylococcus aureus, and Streptococcus pyogenes remain the principal pathogens. Chest ultrasound is preferred for characterizing pleural collections and guiding intervention, whereas computed tomography is reserved for atypical disease or suspected complications. Small pediatric comparative trials report broadly similar outcomes for catheter drainage with fibrinolysis and video-assisted thoracoscopic surgery (VATS), but differences in sample size, eligibility, treatment protocols, and outcome definitions limit conclusions about comparative effectiveness. Image-guided small-bore catheter drainage with protocol-based urokinase or tissue plasminogen activator is effective for many loculated effusions. Pediatric evidence does not support routine addition of DNase. Comparative trials show broadly similar clinical outcomes for fibrinolysis and video-assisted thoracoscopic surgery, although heterogeneous protocols and limited sample sizes preclude identification of a universally superior strategy. Thoracotomy is rarely required. Conclusions: Management should integrate respiratory and septic severity, pleural anatomy, microbiology, adequacy of drainage, clinical trajectory, and local expertise rather than rely on rigid staging. Long-term recovery is excellent in most previously healthy children receiving timely treatment. Standardized definitions, pediatric outcome sets, multicenter comparative trials, validated predictors of treatment failure, and studies of antimicrobial duration remain important research priorities.

PMID 43030349
阅读全文 →
PubMedBMC neurology2026-11-12

Efficacy and safety of urokinase intravenous thrombolysis in minor stroke according to large vessel occlusion status: a subgroup analysis of the TRUST trial.

Tao Yongli Y, Fang Hui H, Zhou Yifang Y, Gao Yuan Y et al.

The risk-benefit profile of thrombolytic therapy in minor stroke patients with large vessel occlusion (LVO) remains uncertain. This post hoc analysis of the TRUST trial (ThRombolysis with Urokinase for minor Stroke Trial) sought to comparatively assess whether the presence of large vessel occlusion (LVO) modifies the efficacy and safety of urokinase intravenous thrombolysis, compared with best medical treatment(BMT), in patients with minor stroke. This post-hoc exploratory analysis included patients from the TRUST trial with available vascular imaging data, categorized in the LVO and the non-LVO group. Each group was further divided into the UK thrombolysis group and the BMT group. Primary efficacy outcome was the proportion of patients achieving a modified Rankin Scale (mRS) score of 0-1 at 90 days. Safety outcomes included symptomatic intracranial hemorrhage (sICH) within 36 h and all-cause mortality within 90 days. Of the 999 patients enrolled in the TRUST trial, 605 were included in the current study. UK thrombolysis was not associated with a 90-day excellent functional outcome in minor stroke patients, either in LVO patients (adjusted risk ratio [RR] 1.90, 95% CI 0.63-2.26) or in non-LVO patients (adjusted RR 1.02, 95% CI 0.84-1.23) compared with the BMT group (p for interaction = 0.41). In the LVO group, UK thrombolysis showed a non-significant trend toward reduced mortality (adjusted RR 0.04, 95% CI 0.01-1.65), whereas no such effect was observed in non-LVO patients (adjusted RR 0.52, 95% CI 0.11-2.52). No significant interaction was found between groups (p for interaction = 0.25). In addition, there were no patients who experienced sICH in subgroup analysis. This subgroup analysis found no improvement in 90-day functional outcomes with UK thrombolysis in minor stroke patients, irrespective of LVO presence, while maintaining a comparable safety profile with regard to mortality and sICH. The TRUST trial was registered with ClinicalTrials. gov (NCT04420351). Registration Date: June 04, 2020.

PMID 43015686
阅读全文 →
PubMedBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2026-11-12

The Plasminogen Activator Inhibitor 1 (PAI-1) paradox in cancer: From tumor microenvironment remodeling to therapeutic targeting.

Bennetot Audrey A, Pagès Gilles G, Dufies Maeva M

Plasminogen activator inhibitor-1 (PAI-1), encoded by the SERPINE1 gene, is a key regulator of the fibrinolytic system through inhibition of the plasminogen activators urokinase (uPA) and tissue-type plasminogen activator (tPA). Although this canonical function would be expected to limit extracellular matrix degradation and tumor invasion, elevated PAI-1 expression is consistently associated with tumor progression and poor clinical outcomes across multiple cancer types. This apparent contradiction, known as the "PAI-1 paradox," highlights the diverse biological functions of PAI-1 beyond fibrinolysis. Within the tumor microenvironment, PAI-1 regulates several hallmarks of cancer through interactions with extracellular matrix components and receptors such as LRP1, uPAR, and integrins. These interactions influence angiogenesis, apoptosis resistance, tumor cell migration, and extracellular matrix remodeling. Emerging evidence also indicates that PAI-1 shapes the immune microenvironment by modulating immune cell recruitment and macrophage polarization, although the underlying mechanisms remain incompletely understood. Clinically, SERPINE1 overexpression correlates with poor prognosis in numerous malignancies, including colorectal, lung, breast, and gastric cancers. Pharmacological targeting of the PAI-1 axis with small-molecule inhibitors or neutralizing antibodies shows antitumor activity in preclinical models, and the oral inhibitor TM5614 has reached phase III clinical trial in chronic myeloid leukemia and melanoma. This narrative review summarizes current knowledge of PAI-1 regulation and function in cancer and discusses therapeutic strategies targeting this pathway.

PMID 43019845
阅读全文 →
PubMedFrontiers in systems biology2026-11-11

From telomere dysfunction to seno-antigen selection: a conceptual framework and route-specific evidence appraisal for senolytic immunotherapy.

Niazi Sarfaraz K SK

Cellular senescence causally contributes to age-related and chronic diseases, rendering the targeted immune clearance of pathological senescent cells a promising therapeutic avenue. Progress remains limited by heterogeneity across cell lineages, tissues, inducing stressors, and temporal factors. As antigen expression alone does not ensure immune accessibility, functional recognition, or safety for healthy tissues, these aspects warrant thorough evaluation. A conceptual framework is proposed, distinct from a validated or implementable algorithm, for identifying and prioritizing senescence-associated antigens. This framework requires four criteria that a single candidate antigen must meet within the same cellular context: persistent pathological senescence, immune accessibility via a confirmed surface antigen or naturally presented human leukocyte antigen (HLA) peptide, modality-appropriate functional immune recognition, and exclusion from vital healthy or beneficially senescent states. The mechanistic origin, such as telomere dysfunction, serves as an optional stratification axis that defines coherent subsets rather than a universal prerequisite; data lacking matched telomere and antigen information in the same cells remain unverified. The process distinguishes target nomination from product validation: evidence of recognition in a single modality, such as chimeric antigen receptor (CAR) targeting of a surface antigen, does not confirm validation for alternatives like peptide vaccines. Application of the framework to urokinase-type plasminogen activator receptor (uPAR) and glycoprotein nonmetastatic melanoma protein B (GPNMB) indicates that neither candidate currently meets all criteria, and the telomere axis remains untested for both. Given that multivalent vaccination elicits immunity against each component independently, combining candidates that fail individual criteria risks amplifying liabilities rather than ensuring intersectional specificity. This outcome would require an engineered AND-gated recognition system, where the capitalized operators AND, OR, and NOT denote Boolean logic gates rather than emphasis. The framework remains in the validation phase. Each criterion receives an ordinal grade, a non-compensatory decision rule, a route-specific ligand-density window that sets the quantitative condition for recognition and healthy-cell sparing, and a predefined seven-compartment counter-screening panel. Recognition architectures are formally compared, and a pre-registered benchmarking study with specified falsification criteria is outlined as the framework's validation test.

PMID 43011401
阅读全文 →
PubMedClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2026-11-10

Fibrinolytic Response to Protein C Zymogen and Plasma in Sepsis-Associated Purpura Fulminans: A Case Series of Nine Consecutive Patients.

Meli Andrea A, Marchesi Tiziana T, Silvestri Ivan I, Caccioppola Alessio A et al.

Purpura fulminans (PF) is a rare and life-threatening manifestation of disseminated intravascular coagulation, leading to multiorgan failure. Protein C (PC) zymogen supplementation has a strong pathophysiological rationale, but its effects on the viscoelastic fibrinolytic profile have not been described. We retrospectively analyzed nine patients (six adults, three children) admitted to our intensive care units between 2017 and 2025 with PF associated with septic shock, treated with PC zymogen concentrate and fresh frozen plasma (FFP). In the six adults, PC and fibrinolysis were measured before and a median of 13 hours after the PC loading dose, fibrinolysis with modified viscoelastic hemostatic assays (urokinase-modified thromboelastography [UK-TEG] in three, tissue plasminogen activator test [TPA-test, ClotPro] in three). Median (interquartile range) PC rose from 23 (10-31)% to 102 (63-137)% and Lysis, the percentage of clot lysis at the modified assays, from 15 (0-47)% to 78 (60-100)%. All six patients had fibrinolysis resistance before treatment. Lysis increased in five and returned within the reference interval in one; in the three TPA-test patients, lysis time became measurable after treatment but remained above 300 s. Three patients died and four required surgery for necrotic skin or soft tissue lesions. PC and FFP administration was followed by a partial recovery of the fibrinolytic response, which cannot be attributed to PC alone, since plasma was given at the same time. Modified viscoelastic assays may help monitor the response to PC and plasma therapy.

PMID 43008776
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多urokinase